Skip to content

Clinical Study on the Intervention of Bufei Xiaojie Formula in the Immune Microenvironment of Pulmonary Nodules Based on the Traditional Chinese Medicine Concept of Preventive Treatment of Disease

Clinical Study on the Intervention of Bufei Xiaojie Formula in the Immune Microenvironment of Pulmonary Nodules Based on the Traditional Chinese Medicine Concept of Preventive Treatment of Disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000867
Enrollment
Unknown
Registered
2025-04-27
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary nodules

Interventions

treatment group:The oral administration of the in-hospital preparation "Bu Fei Xiao Jie Fang

Sponsors

Shenzhen Hospital Of Guangzhou University Of Chinese Medincine(Futian)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Meet the diagnostic criteria for pulmonary nodules in both traditional Chinese and Western medicine and have signed an informed consent form; 2.The pulmonary nodules are solid pure ground-glass nodules (pGGN) or mixed ground-glass nodules (mGGN) with a diameter between 5 and 10mm; 3.Good compliance able to adhere to medication for 4 months; 4.Cooperative able to seriously complete observation scales; 5.No gender restrictions age between 20 and 65 years old.

Exclusion criteria

Exclusion criteria: 1.Pulmonary nodules with a maximum diameter less than 5mm (small nodules) or nodules with a diameter greater than 10mm; 2.Those with atelectasis enlarged pulmonary hilar lymph nodes and pleural effusion or those with other systemic tumors; 3.Those with severe heart liver kidney or other organ diseases or those with neurological disorders that cannot cooperate; 4.Those with poor compliance who cannot adhere to follow-up and medication; 5.Those currently participating in other clinical studies.

Design outcomes

Primary

MeasureTime frame
Immune Microenvironment Indicators;

Secondary

MeasureTime frame
Bronchial provocation test;FeNO test;Chest CT;TCM Symptom Score;Lung cancer autoantibody panel testing;Pulmonary ventilation function;

Countries

China

Contacts

Public ContactXu Weifang

Shenzhen Hospital Of Guangzhou University Of Chinese Medincine(Futian)

2487317006@qq.com13528895687

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026